Imojev
Details for Imojev vaccine and its components.
Sponsor:
Sanofi-Aventis Australia
Administration route:
Subcutaneous injection
Vaccine group:
Japanese encephalitis vaccines
Registered for use in people aged ≥9 months.
Live attenuated Japanese encephalitis vaccine
Lyophilised powder in a monodose vial with separate diluent.
Each 0.5 mL reconstituted dose contains:
- 4.0–5.8 log plaque-forming units of live attenuated recombinant Japanese encephalitis virus
- mannitol
- lactose
- glutamic acid
- potassium hydroxide
- histidine
- human serum albumin
No adjuvants or antibiotics are added.
For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/imojev.